237 related articles for article (PubMed ID: 16221377)
1. New paradigms for therapy for osteosarcoma.
Nagarajan R; Clohisy D; Weigel B
Curr Oncol Rep; 2005 Nov; 7(6):410-4. PubMed ID: 16221377
[TBL] [Abstract][Full Text] [Related]
2. A Review of T-Cell Related Therapy for Osteosarcoma.
Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
[TBL] [Abstract][Full Text] [Related]
3. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
Pratt HG; Justin EM; Lindsey BA
Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
[TBL] [Abstract][Full Text] [Related]
4. Progress and opportunities for immune therapeutics in osteosarcoma.
Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
6. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
8. The immunotherapy of canine osteosarcoma: a historical and systematic review.
Wycislo KL; Fan TM
J Vet Intern Med; 2015; 29(3):759-69. PubMed ID: 25929293
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells for osteosarcoma.
Tarek N; Lee DA
Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic orientation in osteogenic sarcomas].
Trifaud A
Rev Chir Orthop Reparatrice Appar Mot; 1974; 60(7):517-30. PubMed ID: 4282165
[No Abstract] [Full Text] [Related]
11. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
12. Osteosarcoma treatment: state of the art.
Ta HT; Dass CR; Choong PF; Dunstan DE
Cancer Metastasis Rev; 2009 Jun; 28(1-2):247-63. PubMed ID: 19214708
[TBL] [Abstract][Full Text] [Related]
13. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma: A comprehensive review of management and treatment strategies.
Jafari F; Javdansirat S; Sanaie S; Naseri A; Shamekh A; Rostamzadeh D; Dolati S
Ann Diagn Pathol; 2020 Dec; 49():151654. PubMed ID: 33130384
[TBL] [Abstract][Full Text] [Related]
15. Novel insights and therapeutic interventions for pediatric osteosarcoma.
Kager L; Tamamyan G; Bielack S
Future Oncol; 2017 Feb; 13(4):357-368. PubMed ID: 27651036
[TBL] [Abstract][Full Text] [Related]
16. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group.
Bielack SS; Kempf-Bielack B; Heise U; Schwenzer D; Winkler K
J Clin Oncol; 1999 Apr; 17(4):1164. PubMed ID: 10561175
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of heterogenous sarcomas: questions and strategies.
Dufresne A; Meurgey A; Brahmi M
Curr Opin Oncol; 2019 Jul; 31(4):304-309. PubMed ID: 31033565
[TBL] [Abstract][Full Text] [Related]
18. Perioperative blood transfusions and survival in osteosarcoma.
Chesi R; Borghi B; Lari S
Cancer Treat Res; 1993; 62():25-8. PubMed ID: 8096741
[No Abstract] [Full Text] [Related]
19. Immunotherapeutic approaches in pediatric osteosarcoma.
Cao H; Zhang H; Zou H
Minerva Pediatr; 2018 Dec; 70(6):635-636. PubMed ID: 28353326
[No Abstract] [Full Text] [Related]
20. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
